Bafna Pharmaceuticals Limited (BOM:532989)
India · Delayed Price · Currency is INR 123.50
-6.20 (-4.78%)
At close: Feb 13, 2026
Bafna Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 1,474 | 1,459 | 1,525 | 1,153 | 851.4 | 712.18 |
Other Revenue | 0 | - | - | - | - | - |
Revenue | 1,474 | 1,459 | 1,525 | 1,153 | 851.4 | 712.18 |
Revenue Growth (YoY) | -0.51% | -4.33% | 32.18% | 35.48% | 19.55% | 67.68% |
Cost of Revenue | 997.08 | 1,034 | 1,073 | 770.12 | 515.41 | 455.05 |
Gross Profit | 477.31 | 424.19 | 452.15 | 383.38 | 336 | 257.13 |
Selling, General & Admin | 226.32 | 216.04 | 198.38 | 166.34 | 149.37 | 122.47 |
Other Operating Expenses | 90.55 | 91.06 | 138.44 | 42.94 | 65.29 | 28.43 |
Operating Expenses | 363.32 | 356.18 | 387.52 | 265.66 | 269.59 | 195.68 |
Operating Income | 113.98 | 68.01 | 64.63 | 117.72 | 66.41 | 61.46 |
Interest Expense | -32.85 | -25.62 | -19.38 | -17.98 | -5.24 | -0.89 |
Interest & Investment Income | 1.36 | 1.36 | 1.25 | 0.45 | 0.34 | 0.4 |
Currency Exchange Gain (Loss) | 13.44 | 13.44 | 16.72 | 14.77 | 3.61 | 3.84 |
Other Non Operating Income (Expenses) | 15.49 | 2.72 | 9.6 | -2.3 | 8.5 | -6.54 |
EBT Excluding Unusual Items | 111.43 | 59.91 | 72.82 | 112.67 | 73.62 | 58.27 |
Gain (Loss) on Sale of Assets | 0.74 | 0.74 | 0.66 | 1.96 | - | - |
Asset Writedown | -21.46 | -21.46 | - | - | - | - |
Other Unusual Items | 3.57 | - | - | - | -21.57 | - |
Pretax Income | 96.61 | 41.53 | 73.48 | 116.16 | 52.16 | 58.27 |
Income Tax Expense | - | - | - | 2.78 | - | - |
Earnings From Continuing Operations | 96.61 | 41.53 | 73.48 | 113.38 | 52.16 | 58.27 |
Net Income to Company | 96.61 | 41.53 | 73.48 | 113.38 | 52.16 | 58.27 |
Net Income | 96.61 | 41.53 | 73.48 | 113.38 | 52.16 | 58.27 |
Net Income to Common | 96.61 | 41.53 | 73.48 | 113.38 | 52.16 | 58.27 |
Net Income Growth | 124.83% | -43.49% | -35.19% | 117.36% | -10.48% | - |
Shares Outstanding (Basic) | 24 | 24 | 24 | 24 | 24 | 24 |
Shares Outstanding (Diluted) | 24 | 24 | 24 | 24 | 24 | 24 |
Shares Change (YoY) | -0.14% | - | - | - | -0.13% | 901.24% |
EPS (Basic) | 4.09 | 1.76 | 3.11 | 4.79 | 2.21 | 2.46 |
EPS (Diluted) | 4.09 | 1.76 | 3.11 | 4.79 | 2.21 | 2.46 |
EPS Growth | 125.13% | -43.49% | -35.15% | 117.23% | -10.36% | - |
Free Cash Flow | - | 2.76 | -60.93 | -17.66 | 21.87 | -197.04 |
Free Cash Flow Per Share | - | 0.12 | -2.58 | -0.75 | 0.93 | -8.32 |
Gross Margin | 32.37% | 29.08% | 29.66% | 33.24% | 39.46% | 36.10% |
Operating Margin | 7.73% | 4.66% | 4.24% | 10.21% | 7.80% | 8.63% |
Profit Margin | 6.55% | 2.85% | 4.82% | 9.83% | 6.13% | 8.18% |
Free Cash Flow Margin | - | 0.19% | -4.00% | -1.53% | 2.57% | -27.67% |
EBITDA | 162.09 | 116.9 | 114.58 | 171.07 | 121.34 | 106.24 |
EBITDA Margin | 10.99% | 8.02% | 7.51% | 14.83% | 14.25% | 14.92% |
D&A For EBITDA | 48.1 | 48.9 | 49.95 | 53.34 | 54.93 | 44.78 |
EBIT | 113.98 | 68.01 | 64.63 | 117.72 | 66.41 | 61.46 |
EBIT Margin | 7.73% | 4.66% | 4.24% | 10.21% | 7.80% | 8.63% |
Effective Tax Rate | - | - | - | 2.40% | - | - |
Revenue as Reported | 1,515 | 1,486 | 1,560 | 1,186 | 868.38 | 719.67 |
Advertising Expenses | - | 3.49 | 4.72 | 3.66 | 0.96 | 0.56 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.